



**First Quarter 2023**  
**Other Financial Disclosures**  
**Table of Contents**

Table 1: Sales by Segment	1
Table 2: Sales by Geographic Area	2
Table 3: Sales of Key Products/Franchises	3 - 8
Table 3a: Supplemental Sales Reconciliation	9
Table 3b: Supplemental Sales Information	10
Table 4: Condensed Consolidated Statement of Earnings - QTD	11
Table 5: Non-GAAP Adjusted Operational Sales Growth - QTD	12
Table 6: Non-GAAP Adjusted Net Earnings	13
Table 7: Non-GAAP IBT by Segment - QTD	14
Table 8: Non-GAAP P&L Reconciliation	15

**Johnson & Johnson and Subsidiaries**
**Supplementary Sales Data**

(Unaudited; Dollars in Millions)		FIRST QUARTER				
		2023	2022	Total	Percent Change	
					Operations	Currency
<b>Sales to customers by segment of business</b>						
Consumer Health						
U.S.	\$	1,735	1,557	11.4 %	11.4	-
International		2,117	2,029	4.4	11.3	(6.9)
		<b>3,852</b>	<b>3,586</b>	7.4	11.3	(3.9)
Pharmaceutical <sup>(1)</sup>						
U.S.		7,023	6,632	5.9	5.9	-
International		6,390	6,237	2.4	8.6	(6.2)
		<b>13,413</b>	<b>12,869</b>	4.2	7.2	(3.0)
Pharmaceutical excluding COVID-19 Vaccine <sup>(1)</sup>						
U.S.		7,023	6,557	7.1	7.1	-
International		5,643	5,855	(3.6)	2.4	(6.0)
		<b>12,666</b>	<b>12,412</b>	2.0	4.9	(2.9)
MedTech <sup>(1)</sup>						
U.S.		3,759	3,225	16.6	16.6	-
International		3,722	3,746	(0.6)	6.2	(6.8)
		<b>7,481</b>	<b>6,971</b>	7.3	11.0	(3.7)
U.S.		12,517	11,414	9.7	9.7	-
International		12,229	12,012	1.8	8.3	(6.5)
Worldwide		<b>24,746</b>	<b>23,426</b>	5.6	9.0	(3.4)
U.S.		12,517	11,339	10.4	10.4	-
International		11,482	11,630	(1.3)	5.2	(6.5)
Worldwide excluding COVID-19 Vaccine <sup>(1)</sup>	\$	<b>23,999</b>	<b>22,969</b>	4.5 %	7.7	(3.2)

**Note:** Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

<sup>(1)</sup> Refer to supplemental sales reconciliation schedule

**Johnson & Johnson and Subsidiaries**  
**Supplementary Sales Data**

	FIRST QUARTER				
	2023	2022	Total	Percent Change	
				Operations	Currency
<b>Sales to customers by geographic area</b>					
U.S.	\$ 12,517	11,414	9.7 %	9.7	-
Europe	6,332	6,024	5.1	10.0	(4.9)
Western Hemisphere excluding U.S.	1,587	1,482	7.1	14.3	(7.2)
Asia-Pacific, Africa	4,310	4,506	(4.3)	4.1	(8.4)
International	12,229	12,012	1.8	8.3	(6.5)
Worldwide	\$ 24,746	23,426	5.6 %	9.0	(3.4)

**Note:** Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



REPORTED SALES vs. PRIOR PERIOD (\$MM)

			FIRST QUARTER		
	<u>2023</u>	<u>2022</u>	<u>Reported</u>	<u>% Change</u> <u>Operational</u> <sup>(1)</sup>	<u>Currency</u>
<b>CONSUMER HEALTH SEGMENT <sup>(2)</sup></b>					
<u>OTC</u>					
US	\$ 745	670	11.0%	11.0%	-
Intl	897	791	13.5%	19.8%	-6.3%
WW	<u>1,642</u>	<u>1,461</u>	12.4%	15.8%	-3.4%
<u>SKIN HEALTH / BEAUTY</u>					
US	617	544	13.4%	13.4%	-
Intl	493	468	5.3%	12.6%	-7.3%
WW	<u>1,110</u>	<u>1,012</u>	9.7%	13.1%	-3.4%
<u>ORAL CARE</u>					
US	159	143	11.6%	11.6%	-
Intl	202	223	-9.6%	-4.0%	-5.6%
WW	<u>361</u>	<u>366</u>	-1.3%	2.1%	-3.4%
<u>BABY CARE</u>					
US	96	85	13.0%	13.0%	-
Intl	263	270	-2.8%	4.5%	-7.3%
WW	<u>359</u>	<u>355</u>	1.0%	6.5%	-5.5%
<u>WOMEN'S HEALTH</u>					
US	3	3	1.8%	1.8%	-
Intl	214	224	-4.9%	4.1%	-9.0%
WW	<u>217</u>	<u>228</u>	-4.8%	4.1%	-8.9%
<u>WOUND CARE / OTHER</u>					
US	115	112	2.6%	2.6%	-
Intl	49	52	-6.0%	2.3%	-8.3%
WW	<u>164</u>	<u>164</u>	-0.1%	2.5%	-2.6%
<b><u>TOTAL CONSUMER HEALTH</u></b>					
US	1,735	1,557	11.4%	11.4%	-
Intl	2,117	2,029	4.4%	11.3%	-6.9%
WW	<u>\$ 3,852</u>	<u>3,586</u>	7.4%	11.3%	-3.9%

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

**PHARMACEUTICAL SEGMENT <sup>(2,3)</sup>**

**IMMUNOLOGY**

	<u>2023</u>	<u>2022</u>	<b>FIRST QUARTER</b>		
			<u>Reported</u>	<u>Operational <sup>(1)</sup></u>	<u>Currency</u>
US	\$ 2,448	2,501	-2.1%	-2.1%	-
Intl	1,664	1,617	2.9%	9.7%	-6.8%
WW	<u>4,112</u>	<u>4,119</u>	-0.2%	2.5%	-2.7%

**REMICADE**

US	276	358	-22.8%	-22.8%	-
US Exports <sup>(4)</sup>	41	80	-48.8%	-48.8%	-
Intl	170	225	-24.4%	-20.0%	-4.4%
WW	<u>487</u>	<u>663</u>	-26.5%	-25.0%	-1.5%

**SIMPONI / SIMPONI ARIA**

US	271	287	-5.6%	-5.6%	-
Intl	266	283	-6.1%	1.8%	-7.9%
WW	<u>537</u>	<u>571</u>	-5.8%	-1.9%	-3.9%

**STELARA**

US	1,451	1,379	5.2%	5.2%	-
Intl	993	909	9.3%	16.2%	-6.9%
WW	<u>2,444</u>	<u>2,288</u>	6.8%	9.6%	-2.8%

**TREMFYA**

US	406	391	3.9%	3.9%	-
Intl	234	199	17.3%	24.9%	-7.6%
WW	<u>640</u>	<u>590</u>	8.4%	11.0%	-2.6%

**OTHER IMMUNOLOGY**

US	3	6	-51.2%	-51.2%	-
Intl	0	0	-	-	-
WW	<u>3</u>	<u>6</u>	-51.3%	-51.3%	0.0%

**INFECTIOUS DISEASES**

US	392	461	-14.9%	-14.9%	-
Intl	1,193	836	42.8%	49.2%	-6.4%
WW	<u>1,586</u>	<u>1,297</u>	22.3%	26.4%	-4.1%

**COVID-19 VACCINE**

US	0	75	*	*	-
Intl	747	382	95.6%	*	-8.9%
WW	<u>747</u>	<u>457</u>	63.4%	70.8%	-7.4%

**EDURANT / rilpivirine**

US	9	9	-1.4%	-1.4%	-
Intl	271	239	13.4%	18.7%	-5.3%
WW	<u>280</u>	<u>248</u>	12.8%	18.0%	-5.2%

**PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA**

US	378	369	2.5%	2.5%	-
Intl	99	132	-25.2%	-21.2%	-4.0%
WW	<u>477</u>	<u>501</u>	-4.8%	-3.7%	-1.1%

**OTHER INFECTIOUS DISEASES**

US	5	8	-33.1%	-33.1%	-
Intl	77	83	-7.6%	-5.6%	-2.0%
WW	<u>82</u>	<u>91</u>	-9.8%	-8.0%	-1.8%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	FIRST QUARTER				
	<u>2023</u>	<u>2022</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational</u> <sup>(1)</sup>	<u>Currency</u>
<b><u>NEUROSCIENCE</u></b>					
US	978	843	16.0%	16.0%	-
Intl	826	898	-8.1%	-3.1%	-5.0%
WW	<u>1,804</u>	<u>1,741</u>	3.6%	6.1%	-2.5%
<u>CONCERTA / Methylphenidate</u>					
US	70	35	*	*	-
Intl	136	122	11.4%	20.2%	-8.8%
WW	<u>206</u>	<u>157</u>	31.4%	38.2%	-6.8%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>					
US	713	661	7.9%	7.9%	-
Intl	331	387	-14.6%	-8.9%	-5.7%
WW	<u>1,044</u>	<u>1,048</u>	-0.4%	1.7%	-2.1%
<u>SPRAVATO</u>					
US	111	61	82.4%	82.4%	-
Intl	20	9	*	*	*
WW	<u>131</u>	<u>70</u>	86.9%	88.0%	-1.1%
<u>OTHER NEUROSCIENCE</u>					
US	84	86	-3.5%	-3.5%	-
Intl	339	380	-10.7%	-7.6%	-3.1%
WW	<u>423</u>	<u>467</u>	-9.4%	-6.9%	-2.5%
<b><u>ONCOLOGY</u></b>					
US	1,889	1,582	19.4%	19.4%	-
Intl	2,223	2,369	-6.1%	-0.1%	-6.0%
WW	<u>4,112</u>	<u>3,950</u>	4.1%	7.7%	-3.6%
<u>CARVYKTI</u>					
US	70	-	*	*	-
Intl	2	-	*	*	-
WW	<u>72</u>	<u>-</u>	*	*	-
<u>DARZALEX</u>					
US	1,191	953	25.0%	25.0%	-
Intl	1,072	903	18.8%	26.4%	-7.6%
WW	<u>2,264</u>	<u>1,856</u>	22.0%	25.7%	-3.7%
<u>ERLEADA</u>					
US	249	206	21.2%	21.2%	-
Intl	293	194	50.9%	60.7%	-9.8%
WW	<u>542</u>	<u>400</u>	35.6%	40.3%	-4.7%
<u>IMBRUVICA</u>					
US	270	370	-27.1%	-27.1%	-
Intl	557	668	-16.6%	-11.7%	-4.9%
WW	<u>827</u>	<u>1,038</u>	-20.3%	-17.2%	-3.1%
<u>ZYTIGA / abiraterone acetate</u>					
US	16	19	-14.0%	-14.0%	-
Intl	229	520	-56.0%	-52.2%	-3.8%
WW	<u>245</u>	<u>539</u>	-54.5%	-50.9%	-3.6%
<u>OTHER ONCOLOGY</u>					
US	92	34	*	*	-
Intl	70	84	-17.2%	-12.1%	-5.1%
WW	<u>162</u>	<u>118</u>	37.4%	41.0%	-3.6%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>FIRST QUARTER</b>				
	<u>2023</u>	<u>2022</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational</u> <sup>(1)</sup>	<u>Currency</u>
<b><u>PULMONARY HYPERTENSION</u></b>					
US	600	572	4.9%	4.9%	-
Intl	272	279	-2.7%	5.3%	-8.0%
WW	<u>872</u>	<u>852</u>	2.4%	5.0%	-2.6%
<u>OPSUMIT</u>					
US	273	273	-0.1%	-0.1%	-
Intl	167	170	-1.6%	6.1%	-7.7%
WW	<u>440</u>	<u>443</u>	-0.7%	2.3%	-3.0%
<u>UPTRAVI</u>					
US	304	269	13.1%	13.1%	-
Intl	58	56	3.3%	9.4%	-6.1%
WW	<u>362</u>	<u>325</u>	11.4%	12.4%	-1.0%
<u>OTHER PULMONARY HYPERTENSION</u>					
US	23	30	-22.4%	-22.4%	-
Intl	47	53	-12.6%	-1.8%	-10.8%
WW	<u>70</u>	<u>83</u>	-16.1%	-9.3%	-6.8%
<b><u>CARDIOVASCULAR / METABOLISM / OTHER</u></b>					
US	715	672	6.3%	6.3%	-
Intl	212	238	-10.8%	-6.3%	-4.5%
WW	<u>927</u>	<u>910</u>	1.8%	3.0%	-1.2%
<u>XARELTO</u>					
US	578	508	13.7%	13.7%	-
Intl	-	-	-	-	-
WW	<u>578</u>	<u>508</u>	13.7%	13.7%	-
<u>OTHER</u>					
US	137	164	-16.7%	-16.7%	-
Intl	212	238	-10.8%	-6.3%	-4.5%
WW	<u>349</u>	<u>402</u>	-13.2%	-10.5%	-2.7%
<b><u>TOTAL PHARMACEUTICAL</u></b>					
US	7,023	6,632	5.9%	5.9%	-
Intl	6,390	6,237	2.4%	8.6%	-6.2%
WW	<u>\$ 13,413</u>	<u>12,869</u>	4.2%	7.2%	-3.0%

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

**MEDETECH SEGMENT <sup>(2,3)</sup>**

**INTERVENTIONAL SOLUTIONS**

	<u>2023</u>	<u>2022</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational <sup>(1)</sup></u>	<u>Currency</u>
US	\$ 863	494	74.5%	74.5%	-
Intl	640	597	7.1%	14.9%	-7.8%
WW	<u>1,503</u>	<u>1,092</u>	37.6%	41.9%	-4.3%

**ELECTROPHYSIOLOGY**

US	571	470	21.4%	21.4%	-
Intl	522	532	-1.8%	6.1%	-7.9%
WW	<u>1,092</u>	<u>1,002</u>	9.1%	13.3%	-4.2%

**ABIOMED**

US	264	-	*	*	-
Intl	60	-	*	*	-
WW	<u>324</u>	<u>-</u>	*	*	-

**OTHER INTERVENTIONAL SOLUTIONS**

US	28	24	17.4%	17.4%	-
Intl	58	65	-11.7%	-5.0%	-6.7%
WW	<u>87</u>	<u>90</u>	-3.9%	1.1%	-5.0%

**ORTHOPAEDICS**

US	1,363	1,289	5.8%	5.8%	-
Intl	881	899	-2.0%	4.0%	-6.0%
WW	<u>2,245</u>	<u>2,188</u>	2.6%	5.1%	-2.5%

**HIPS**

US	241	225	7.3%	7.3%	-
Intl	149	164	-9.0%	-3.6%	-5.4%
WW	<u>390</u>	<u>389</u>	0.4%	2.7%	-2.3%

**KNEES**

US	226	201	12.4%	12.4%	-
Intl	142	138	3.4%	9.6%	-6.2%
WW	<u>368</u>	<u>339</u>	8.7%	11.3%	-2.6%

**TRAUMA**

US	491	475	3.2%	3.2%	-
Intl	267	273	-2.4%	3.6%	-6.0%
WW	<u>757</u>	<u>748</u>	1.2%	3.4%	-2.2%

**SPINE, SPORTS & OTHER**

US	406	387	4.7%	4.7%	-
Intl	323	324	-0.3%	5.9%	-6.2%
WW	<u>729</u>	<u>712</u>	2.4%	5.2%	-2.8%



**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	FIRST QUARTER				
	2023	2022	% Change		Currency
			Reported	Operational <sup>(1)</sup>	
<b><u>SURGERY</u></b>					
US	975	921	5.9%	5.9%	-
Intl	1,459	1,513	-3.6%	3.1%	-6.7%
WW	<u>2,434</u>	<u>2,434</u>	0.0%	4.1%	-4.1%
<b><u>ADVANCED</u></b>					
US	444	417	6.5%	6.5%	-
Intl	673	729	-7.6%	-1.1%	-6.5%
WW	<u>1,118</u>	<u>1,146</u>	-2.5%	1.6%	-4.1%
<b><u>GENERAL</u></b>					
US	531	504	5.4%	5.4%	-
Intl	785	784	0.2%	7.0%	-6.8%
WW	<u>1,316</u>	<u>1,288</u>	2.2%	6.4%	-4.2%
<b><u>VISION</u></b>					
US	558	521	7.1%	7.1%	-
Intl	743	736	0.8%	8.0%	-7.2%
WW	<u>1,300</u>	<u>1,257</u>	3.4%	7.6%	-4.2%
<b><u>CONTACT LENSES / OTHER</u></b>					
US	444	400	11.1%	11.1%	-
Intl	509	511	-0.3%	7.9%	-8.2%
WW	<u>953</u>	<u>910</u>	4.7%	9.3%	-4.6%
<b><u>SURGICAL</u></b>					
US	114	121	-6.0%	-6.0%	-
Intl	233	226	3.3%	8.0%	-4.7%
WW	<u>347</u>	<u>347</u>	0.1%	3.1%	-3.0%
<b><u>TOTAL MEDTECH</u></b>					
US	3,759	3,225	16.6%	16.6%	-
Intl	3,722	3,746	-0.6%	6.2%	-6.8%
WW	<u>\$ 7,481</u>	<u>6,971</u>	7.3%	11.0%	-3.7%

**Note:** Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

\* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures; refer to supplemental sales schedules

(4) Reported as U.S. sales

**Supplemental Sales Reconciliation (Unaudited)**

(Dollars in Millions)

<b>FIRST QUARTER</b>					
			Percent Change		
	2023	2022	Total	Operations	Currency
<b>Pharmaceutical</b>					
U.S.	\$ 7,023	6,632	5.9 %	5.9	-
International	6,390	6,237	2.4	8.6	(6.2)
<b>Worldwide</b>	<b>13,413</b>	<b>12,869</b>	<b>4.2</b>	<b>7.2</b>	<b>(3.0)</b>
<b>COVID-19 Vaccine</b>					
U.S.	0	75	*	*	-
International	747	382	95.6	*	(8.9)
<b>Worldwide</b>	<b>747</b>	<b>457</b>	<b>63.4</b>	<b>70.8</b>	<b>(7.4)</b>
<b>Pharmaceutical excluding COVID-19 Vaccine</b>					
U.S.	7,023	6,557	7.1	7.1	-
International	5,643	5,855	(3.6)	2.4	(6.0)
<b>Worldwide</b>	<b>12,666</b>	<b>12,412</b>	<b>2.0</b>	<b>4.9</b>	<b>(2.9)</b>
<b>Worldwide</b>					
U.S.	12,517	11,414	9.7	9.7	-
International	12,229	12,012	1.8	8.3	(6.5)
<b>Worldwide</b>	<b>24,746</b>	<b>23,426</b>	<b>5.6</b>	<b>9.0</b>	<b>(3.4)</b>
<b>COVID-19 Vaccine</b>					
U.S.	0	75	*	*	-
International	747	382	95.6	*	(8.9)
<b>Worldwide</b>	<b>747</b>	<b>457</b>	<b>63.4</b>	<b>70.8</b>	<b>(7.4)</b>
<b>Worldwide</b>					
U.S.	12,517	11,339	10.4	10.4	-
International	11,482	11,630	(1.3)	5.2	(6.5)
<b>Worldwide excluding COVID-19 Vaccine</b>	<b>\$ 23,999</b>	<b>22,969</b>	<b>4.5 %</b>	<b>7.7</b>	<b>(3.2)</b>

**Note:** Columns and rows within tables may not add due to rounding

\* Percentage greater than 100% or not meaningful

**Supplemental Sales Information**  
(Dollars in Millions)

Certain prior year amounts have been reclassified to conform to current year product disclosures

	2021	2022				2022
	Full Year	Q1	Q2	Q3	Q4	Full Year
<b>PHARMACEUTICAL SEGMENT <sup>(1)</sup></b>						
<b>NEUROSCIENCE</b>						
<b>SPRAVATO</b>						
US	198	61	74	88	105	328
INTL	26	9	11	12	14	46
WW	224	70	85	100	119	374
<b>OTHER NEUROSCIENCE <sup>(2)</sup></b>						
US	427	86	93	106	91	376
INTL	1,647	380	341	286	351	1,358
WW	2,074	467	433	393	442	1,734
<b>ONCOLOGY</b>						
<b>CARVYKTI</b>						
US	-	-	24	55	54	133
INTL	-	-	-	-	-	-
WW	-	-	24	55	54	133
<b>OTHER ONCOLOGY</b>						
US	110	34	33	37	52	156
INTL	458	84	72	64	63	283
WW	568	118	106	100	114	438
<b>CARDIOVASCULAR / METABOLISM / OTHER</b>						
<b>OTHER <sup>(3)</sup></b>						
US	754	164	148	147	110	569
INTL	927	238	215	198	194	845
WW	1,682	402	363	345	304	1,414
<b>MEDTECH SEGMENT <sup>(1)</sup></b>						
<b>INTERVENTIONAL SOLUTIONS</b>						
<b>ELECTROPHYSIOLOGY</b>						
US	1,730	470	499	520	547	2,036
INTL	1,893	532	469	453	447	1,901
WW	3,623	1,002	968	973	994	3,937
<b>ABIOMED <sup>(4)</sup></b>						
US	-	-	-	-	31	31
INTL	-	-	-	-	-	-
WW	-	-	-	-	31	31
<b>OTHER INTERVENTIONAL SOLUTIONS</b>						
US	106	24	26	27	25	102
INTL	242	65	56	60	48	230
WW	348	90	81	87	73	332

**Note:** Columns and rows within tables may not add due to rounding

(1) Unaudited

(2) Other Neuroscience is inclusive of RISPERDAL CONSTA, which was previously disclosed separately

(3) Other is inclusive of INVOKANA, which was previously disclosed separately

(4) Acquired on December 22, 2022

Johnson & Johnson and Subsidiaries  
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

FIRST QUARTER

	2023		2022		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 24,746	100.0	\$ 23,426	100.0	5.6
Cost of products sold	8,395	33.9	7,598	32.4	10.5
Gross Profit	16,351	66.1	15,828	67.6	3.3
Selling, marketing and administrative expenses	6,138	24.8	5,938	25.4	3.4
Research and development expense	3,563	14.4	3,462	14.8	2.9
In-process research and development	49	0.2	610	2.6	
Interest (income) expense, net	(20)	(0.1)	(12)	(0.1)	
Other (income) expense, net	7,228	29.2	(102)	(0.4)	
Restructuring	130	0.6	70	0.3	
Earnings/(Loss) before provision for taxes on income	(737)	(3.0)	5,862	25.0	(112.6)
Provision for/(Benefit from) taxes on income	(669)	(2.7)	713	3.0	(193.8)
Net earnings/(Loss)	\$ (68)	(0.3)	\$ 5,149	22.0	(101.3)
Net earnings/(Loss) per share (Basic/Diluted)*	\$ (0.03)		\$ 1.93		(101.6)
Average shares outstanding (Basic/Diluted)*	2,605.5		2,666.5		
Effective tax rate	90.8 %		12.2 %		

Adjusted earnings before provision for taxes and net earnings <sup>(1)</sup>					
Earnings before provision for taxes on income	\$ 8,468	34.2	\$ 8,218	35.1	3.0
Net earnings	\$ 7,068	28.6	\$ 7,129	30.4	(0.9)
Net earnings per share (Diluted)	\$ 2.68		\$ 2.67		0.4
Average shares outstanding (Diluted)**	2,634.3		2,666.5		
Effective tax rate	16.5 %		13.3 %		

\* Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive.

\*\* Difference of 28.8 shares due to anti-dilutive impact on net loss position.

<sup>(1)</sup> See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth  
FIRST QUARTER 2023 ACTUAL vs. 2022 ACTUAL

	Segments			
	Consumer Health	Pharmaceutical	MedTech	Total
<b>WW As Reported</b>	<b>7.4%</b>	<b>4.2%</b>	<b>7.3%</b>	<b>5.6%</b>
U.S.	11.4%	5.9%	16.6%	9.7%
International	4.4%	2.4%	(0.6)%	1.8%
<b>WW Currency</b>	<b>(3.9)</b>	<b>(3.0)</b>	<b>(3.7)</b>	<b>(3.4)</b>
U.S.	-	-	-	-
International	(6.9)	(6.2)	(6.8)	(6.5)
<b>WW Operational</b>	<b>11.3%</b>	<b>7.2%</b>	<b>11.0%</b>	<b>9.0%</b>
U.S.	11.4%	5.9%	16.6%	9.7%
International	11.3%	8.6%	6.2%	8.3%
<b>Abiomed</b>			<b>(4.6)</b>	<b>(1.4)</b>
U.S.			(8.2)	(2.3)
International			(1.6)	(0.5)
<b>All Other Acquisitions and Divestitures</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>
U.S.	0.0	0.0	0.0	0.0
International	0.0	0.2	0.0	0.1
<b>WW Adjusted Operational</b>	<b>11.3%</b>	<b>7.2%</b>	<b>6.4%</b>	<b>7.6%</b>
U.S.	11.4%	5.9%	8.4%	7.4%
International	11.3%	8.8%	4.6%	7.9%

**Note:** Percentages are based on actual, non-rounded figures and may not sum

**Johnson & Johnson and Subsidiaries**  
**Reconciliation of Non-GAAP Financial Measures**

	First Quarter	
(Dollars in Millions Except Per Share Data)	2023	2022
Net Earnings/(Loss), after tax- as reported	(\$68)	\$5,149
Pre-tax Adjustments		
Litigation expense	6,900	-
Intangible Asset Amortization expense	1,204	1,108
COVID-19 Vaccine related costs <sup>1</sup>	444	-
Consumer Health separation costs	300	102
Restructuring related <sup>2</sup>	130	72
(Gains)/losses on securities	72	411
Medical Device Regulation <sup>3</sup>	64	60
IPR&D	49	610
Acquisition, integration and divestiture related	42	-
Other	-	(7)
Tax Adjustments		
Tax impact on special item adjustments <sup>4</sup>	(2,057)	(393)
Consumer Health separation tax related costs	11	96
Tax legislation and other tax related	(23)	(79)
Adjusted Net Earnings, after tax	<u>\$7,068</u>	<u>\$7,129</u>
Average shares outstanding (Diluted)	2,634.3	2,666.5
Adjusted net earnings per share (Diluted)	<b>\$2.68</b>	<b>\$2.67</b>
Operational adjusted net earnings per share (Diluted)	<b>\$2.75</b>	

**Notes:**

<sup>1</sup> COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.

<sup>2</sup> In the first quarter of 2023, the company completed a prioritization of its research and development (R&D) investment within the Pharmaceutical segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, HIV and hepatitis. The restructuring expenses of \$130 million in the quarter include the termination of partnered and non-partnered program costs and asset impairments.

<sup>3</sup> European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company's previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024.

<sup>4</sup> The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measures

Q1 YTD - Income Before Tax by Segment  
Dollars in Millions

	Consumer Health		Pharmaceutical		MedTech		Unallocated		Consumer Health Separation Costs		Worldwide Total	
	2023	2022	2023	2022	2023	2022	2023	2022	2023	2022	2023	2022
Reported Income Before Tax by Segment	\$ 776	686	4,444	3,924	1,445	1,477	(7,102)	(123)	(300)	(102)	(737)	5,862
<b>% to Sales</b>	<b>20.1%</b>	<b>19.1%</b>	<b>33.1%</b>	<b>30.5%</b>	<b>19.3%</b>	<b>21.2%</b>	<b>-28.7%</b>	<b>-0.5%</b>	<b>-1.2%</b>	<b>-0.4%</b>	<b>-3.0%</b>	<b>25.0%</b>
Intangible asset amortization expense	82	94	739	760	383	254	-	-	-	-	1,204	1,108
In-process research and development	-	-	-	610	49	-	-	-	-	-	49	610
Litigation related	-	-	-	-	-	-	6,900	-	-	-	6,900	-
COVID-19 Vaccine related costs	-	-	444	-	-	-	-	-	-	-	444	-
Loss/(gain) on securities	-	-	38	394	34	17	-	-	-	-	72	411
Restructuring related	-	14	130	(14)	-	72	-	-	-	-	130	72
Acquisition, integration and divestiture related	-	-	-	-	42	-	-	-	-	-	42	-
Medical Device Regulation	-	-	-	-	64	60	-	-	-	-	64	60
Consumer Health separation costs	-	-	-	-	-	-	-	-	300	102	300	102
Other	-	-	-	-	-	-	-	(7)	-	-	-	(7)
Adjusted Income Before Tax by Segment	\$ 858	794	5,795	5,674	2,017	1,880	(202)	(130)	-	-	8,468	8,218
<b>% to Sales</b>	<b>22.3%</b>	<b>22.1%</b>	<b>43.2%</b>	<b>44.1%</b>	<b>27.0%</b>	<b>27.0%</b>	<b>-0.8%</b>	<b>-0.6%</b>	<b>0.0%</b>	<b>0.0%</b>	<b>34.2%</b>	<b>35.1%</b>

**Johnson & Johnson and Subsidiaries**  
**GAAP to Non-GAAP Reconciliation**  
 \$ in Millions

	First Quarter April 2, 2023 GAAP	Intangible asset amortization	Litigation related	In-process research and development	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	First Quarter April 2, 2023 Non-GAAP
Cost of products sold	\$ 8,395	(1,200)			-			(23)	(206)	(12)				6,954
Selling, marketing and admin expenses	6,138							(7)		(38)				6,093
Research and development expense	3,563					(16)		(34)	(16)	(2)				3,495
Other (Income) / Expense	7,228	(4)	(6,900)		-	(26)	(72)		(222)	(285)			-	(281)
In-process research and development	49			(49)										-
Interest (Income) / Expense	(20)									37				17
Restructuring	130				(130)									-
Provision for/(Benefit from) taxes on income	(669)	194	1,622	11	32	5	16	12	105	60	(11)	23	-	1,400
Net Earnings/(Loss)	(68)	1,010	5,278	38	98	37	56	52	339	240	11	(23)	-	7,068

  

	First Quarter April 3, 2022 GAAP	Intangible asset amortization	Litigation related	In-process research and development	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	First Quarter April 3, 2022 Non-GAAP
Cost of products sold	\$ 7,598	(1,108)			(16)			(22)						6,452
Selling, marketing and admin expenses	5,938							(6)						5,932
Research and development expense	3,462							(32)						3,430
Other (Income) / Expense	(102)	-	-		14	-	(411)			(102)			7	(594)
In-process research and development	610			(610)										-
Restructuring	70				(70)									-
Provision for taxes on income	713	168	(53)	138	12	-	96	11	-	23	(96)	79	(2)	1,089
Net Earnings	5,149	940	53	472	60	-	315	49	-	79	96	(79)	(5)	7,129